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IL-2 Regulates Expression of C-MAF in Human CD4 T Cells
Aradhana Rani,*,†,1 Behdad Afzali,†,1 Audrey Kelly,‡ Lemlem Tewolde-Berhan,*
Mark Hackett,* Aditi S. Kanhere,x Isabela Pedroza-Pacheco,{ Holly Bowen,‡
Stipo Jurcevic,† Richard G. Jenner,x David J. Cousins,‡ Jack A. Ragheb,‖
Paul Lavender,‡ and Susan John*
Blockade of IL-2R with humanized anti-CD25 Abs, such as daclizumab, inhibits Th2 responses in human T cells. Recent murine
studies have shown that IL-2 also plays a significant role in regulating Th2 cell differentiation by activated STAT5. To explore the
role of activated STAT5 in the Th2 differentiation of primary human T cells, we studied the mechanisms underlying IL-2 regulation
of C-MAF expression. Chromatin immunoprecipitation studies revealed that IL-2 induced STAT5 binding to specific sites in the
C-MAF promoter. These sites corresponded to regions enriched for markers of chromatin architectural features in both resting CD4
and differentiated Th2 cells. Unlike IL-6, IL-2 induced C-MAF expression in CD4 T cells with or without prior TCR stimulation.
TCR-induced C-MAF expression was significantly inhibited by treatment with daclizumab or a JAK3 inhibitor, R333. Further-
more, IL-2 and IL-6 synergistically induced C-MAF expression in TCR-activated T cells, suggesting functional cooperation
between these cytokines. Finally, both TCR-induced early IL4 mRNA expression and IL-4 cytokine expression in differentiated
Th2 cells were significantly inhibited by IL-2R blockade. Thus, our findings demonstrate the importance of IL-2 in Th2 differ-
entiation in human T cells and support the notion that IL-2R–directed therapies may have utility in the treatment of allergic
disorders. The Journal of Immunology, 2011, 187: 3721–3729.
S
ignal transducers and activators of transcription proteins
are activated by a variety of cytokines, growth factors, and
hormones. They comprise an evolutionarily conserved
family of seven proteins in the mammalian genome (1). These
proteins regulate vital cellular functions such as proliferation,
survival, and differentiation. The two STAT5 proteins, STAT5a and
STAT5b, are activated by members of the gc family of cytokines
(IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21), which together regulate
lymphoid development, differentiation, and survival of various
components of the immune system (2). Studies with knockout and
transgenic mice have shown that Stat5a/5b are essential for the
development and/or homeostatic maintenance of T cells, including
CD8, gd TCR, CD4+CD25+Foxp3+ regulatory T cells (Tregs), and,
most importantly for our studies, the selective differentiation of
CD4 Th cells (3–8).
T cell differentiation involves epigenetic changes in lineage-
associated genes by covalent modifications of DNA and histones
and the histone variant H2A.Z (9). Transcriptionally active regions
of chromatin are generally enriched with several modifications of
histones such as mono-, di-, and trimethylation of H3K4 (8, 10,
11) and H2A.Z (12), which differentially demarcate promoter
and enhancer regions or regions of nucleosomal instability, re-
spectively. A number of different STAT proteins, including Stat5,
interact with transcriptional regulatory regions and are known to
regulate T cell differentiation by enhancing or repressing key genes
involved in these processes (13). Th2 differentiation in both
mouse and human CD4 T cells is critically dependent on IL-2 (14,
15). Consistently, Stat5a knockout mice show defective Th2 re-
sponses and decreased IL-4 production, whereas a constitutively
active Stat5a mutant can restore IL-4 production in IL-2–deficient
CD4 T cells and Th2 differentiation in IL-4Ra–deficient CD4
T cells (6, 16). IL-2–activated Stat5 is necessary for increased
transcription and cell surface expression of IL-4R in differentiat-
ing Th2 cells (17), as well as for appropriate chromatin remod-
eling to enhance accessibility of the murine Il4 locus (16, 18).
Additionally, genome-wide analysis of Stat5 DNA binding in fully
differentiated murine Th2 cells reveals several probable Stat5
binding sites, suggesting that Stat5 can potentially regulate nu-
merous Th2-associated factors (17).
The c-maf proto-oncogene was the first lineage-specific factor
identified for Th2 cells and belongs to the AP-1 family of proteins
(19). It binds to a Maf recognition element (MARE) site in the Il4
promoter and directly transactivates Il4 gene transcription (19).
Overexpression of c-maf in murine Th1 clones induces low levels
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of endogenous IL-4 synthesis, whereas transgenic mice over-
expressing CD4-specific c-maf preferentially develop a Th2 phe-
notype and have attenuated production of the Th1 cytokine IFN-g
(20). Recent studies have also shown that c-maf is required for the
efficient development of murine T follicular helper and Th17
lineages, as well as for the production of IL-10 by Th17 cells (21–
23). Thus, c-maf plays essential roles in the differentiation and
function of multiple effector T cell lineages. In murine T cells,
c-maf expression is regulated by IL-6–activated Stat3 (24). How-
ever, relatively little is known about the regulation of C-MAF
transcription during early human T cell activation prior to dif-
ferentiation.
In this study, to our knowledge we show for the first time that in
primary human CD4 T cells, C-MAF expression is regulated by IL-
2R–mediated STAT5 activation, independently of TCR signaling.
We elucidate upstream regions of the C-MAF gene containing
epigenetic modifications corresponding to transcriptional enhancer
regions in undifferentiated and fully differentiated Th1 and Th2
cells and reveal that these are stably maintained irrespective of the
differentiation state. We show that IL-2 induces in vivo STAT5
binding to IFN-g activation site (GAS) motifs located within and
around these regions of stable epigenetic modifications, and we
characterize their role in regulating IL-2–induced C-MAF tran-
scription. Furthermore, we show that blockade of IL-2R has a pro-
found inhibitory effect on IL-4 production during in vitro Th2
differentiation. These findings indicate that IL-2 plays an important
role in the initiation of Th2 differentiation in human T cells and
support the notion that IL-2R–directed therapies may have utility in
the treatment of allergic disorders (15).
Materials and Methods
PBMCs and CD4 T cell isolation, culture, and treatment
PMBCs were isolated from buffy coats from healthy donors (purchased
from National Blood Service, Tooting, U.K.) by density gradient centri-
fugation using LSM 1077 (PAA Laboratories). CD4 T cells were purified
from PBMCs by positive selection with human CD4 microbeads (Miltenyi
Biotec) according to the manufacturer’s instructions. The purity of CD4
T cells ranged from 93 to 96% by FACS analysis using FITC-conjugated
anti-CD3 and PE-conjugated anti-CD4 mAbs (both from Dako) on a
FACSCalibur instrument (BD Biosciences). Cells were maintained in
culture medium of RPMI 1640 supplemented with 10% FBS (both from
PAA Laboratories) and 2 mM L-glutamine and penicillin/streptomycin
(100 IU/ml and 100 mg/ml, respectively; both from Sigma-Aldrich, Dor-
set, U.K.). When indicated, CD4 T cells were stimulated with 2 mg/ml
PHA-L (EY Laboratories, San Mateo, CA) for 72 h and rested in culture
medium for $16 h prior to activation with 100 U/ml IL-2 (Roche Diag-
nostics). CD4 T cells were activated via the TCR by stimulation with plate-
bound anti-CD3 (UCHT1; 10 mg/ml) and soluble anti-CD28 Ab (2 mg/ml;
both from Ancell) with or without the JAK3 inhibitor R333 (5 mM; a gift
from Rigel Pharmaceuticals, South San Francisco, CA). IL-6 (R&D Sys-
tems) was used at 10 ng/ml for stimulation experiments. CD4 T cells were
inhibited by treatment with anti-human IL-2 Ab (10 mg/ml; BioSource)
or humanized anti-Tac (HAT, or daclizumab; 10 mg/ml; provided by
Hoffmann-La Roche, Nutley, NJ).
Chromatin immunoprecipitation cloning and chromatin
immunoprecipitation sequencing
Chromatin immunoprecipitation (ChIP) cloning experiments were per-
formed using 1.5 3 107 CD4 T cells stimulated with IL-2 for 20 min
followed by a 10-min crosslink with formaldehyde (0.37%) at 37˚C, as
previously described (25). The sonicated chromatin was immunoprecipi-
tated for an hour using mMACS protein A microbeads (Miltenyi Biotec)
and anti-Stat5a or anti-Stat5b monoclonal or control mouse IgG Abs (all
from Zymed Laboratories). Purified chromatin was blunt-end repaired
using T4 DNA polymerase (New England Biolabs), ligated to linkers,
PCR amplified, and cloned into TOPO vector (Invitrogen) and sequenced
(Cogenics).
For identification of the sequences enriched in regions associated with
specific histone phenotypes (ChIP assay coupled with massive parallel
sequencing, or ChIP-seq experiments), ChIP was performed on native
chromatin from ex vivo-differentiated human Th2 cells (26). Chromatin
was prepared by using the protocol of Feil and colleagues (http://www.
epigenome-noe.net/researchtools/protocol.php?protid=2) with some minor
modifications. Briefly, nuclei were treated with micrococcal nuclease
(10 U/ml, 7 min) and mono- and dinucleosomal chromatin was recovered.
Chromatin quality was assessed by agarose gel electrophoresis and semi-
quantitated using a nanodrop. Chromatin (20 mg) was immunoprecipitated
with 3 mg anti-H3K4me3 (ab8580) or anti-IgG control and magnetic
protein G beads (Active Motif). Prior to sequencing, the diversity of
sequences enriched by ChIP was assessed by comparing quantitative PCR
(qPCR) of input DNAwith anti-IgG or anti-H3K4me3 immunoprecipitated
DNA using multiple probe sets (ChIP-qPCR). ChIP libraries were prepared
from amplified DNA (17 cycles) from two biological replicates of Th2
cells (Illumina) according to the manufacturer’s protocol. DNA from
separate experiments was sequenced on GAII genome analyzers (genomics
core facility at the National Institute for Health Research at Guy’s and
St. Thomas’ NHS Foundation Trust/King’s College London Comprehen-
sive Biomedical Research Centre, King’s College London). Detection of
regions of enriched H3K4me3 relative to input DNA was performed by
using MACS and SICER programs. Output was converted to browser
extensible data files displaying the number of tags in 200 bp windows and
visualized within the University of California at Santa Cruz genome
browser.
Preparation of cell extracts and Western blotting
Nuclear and total cell extracts were prepared as described previously (27).
Samples were resolved on 8% SDS-PAGE gels and transferred to Immo-
bilon polyvinylidene difluoride membranes (Millipore). Western blots
were performed using pan-STAT5 (Invitrogen), anti–phospho-STAT5Y694
(New England Biolabs), c-maf polyclonal Ab (M-153; Santa Cruz Bio-
technology), and anti-lamin B or anti-tubulin Abs (both from Invitrogen)
and developed using ECL Plus chemiluminescence reagent (GE Health-
care, Buckinghamshire, U.K.).
RNA isolation and quantitative real-time PCR
Total RNAwas extracted using TRIzol reagent (Invitrogen). RNA (250 ng)
was reverse-transcribed to cDNA using RevertAid H Minus M-MuLV
Reverse Transcriptase (Fermentas) following the manufacturer’s instruc-
tions. Quantitative real-time PCR (qRT-PCR) was performed in triplicate
using 23 Precision SYBR Green MasterMix (PrimerDesign, South-
ampton, U.K.) in a total reaction volume of 20 ml using the ABI Prism
7900 HT sequence detection system (Applied Biosystems), although ChIP-
qPCR reactions were performed in duplicate. The human PPIA or 18S
rRNA genes were used as reference controls for the various experiments.
Cycle threshold values were exported with the sequence detector SDS
2.3 software (Applied Biosystems). Gene-specific primers for PPIA, 18S
rRNA, C-MAF, CD25, and IL2 were obtained from PrimerDesign. The
sequences of all other primers are given in Supplemental Fig. 3.
Luciferase reporter assay
HEK293T cells were cultured and transfected to reconstitute IL-2R sig-
naling using the calcium phosphate method, as previously described (28).
Trimerized GAS1–4 sequences were synthesized (MWG Biotec), cloned
into pGL4.23 vector (Promega), and verified by sequencing (Cogenics).
Luciferase assays were performed by using the Dual-Glo luciferase kit
(Promega) according to the manufacturer’s instructions. Firefly luciferase
activities were standardized to the corresponding Renilla luciferase ac-
tivities for each sample to control for transfection efficiencies.
Th2 skewing and intracellular cytokine staining
Fresh cord blood units were obtained from the Programa Concordia Banc de
Sang i Teixits (Barcelona, Spain) with prior consent of patients and ethical
committee approval. Cord blood units were diluted 1:1 with RPMI 1640
(Lonza) supplemented with 0.6% trisodium citrate and 40 nM 2-ME. Cord
blood mononuclear cells were separated by density gradient centrifugation
using Ficoll-Paque Premium (GE Healthcare UK). CD4 T cells were
isolated by negative selection using a Miltenyi Biotec isolation kit. Mean
(6SD) positivity for CD45RA on isolated CD4 cells was 93 6 5% (n = 3).
Cord blood CD4 cells (0.5–1 million) were activated with IL-2 as follows:
anti-CD3 (10 mg/ml), anti-CD28 (2 mg/ml; both BD Biosciences), and
IL-2 (30 U/ml) without or with HAT (10 mg/ml). Th2 skewing was per-
formed as previously described (26); cord blood CD4 cells (0.5–1 million)
were stimulated with anti-CD3 (10 mg/ml), anti-CD28 (2 mg/ml), IL-2
(30 U/ml), IL-4 (12.5 ng/ml; NBS Biologics), anti–IFN-g and anti–IL-10
(both 5 mg/ml; BD Biosciences) without or with HAT (10 mg/ml).
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Intracellular staining for IL-4 and IFN-g was carried out according
to standard methods. Briefly, cultured cells were restimulated with PMA
(50 ng/ml) and ionomycin (1 mM; both from Sigma-Aldrich) for 4.5 h at
37˚C in the presence of brefeldin A (3 mg/ml; eBioscience) in 1 ml culture
medium.Washed cells were fixed with 4% PFA, blocked with 50% FCS (v/v
in PBS), permeabilized with 0.1% saponin (w/v in 1% FCS in PBS), and
stained for 30 min in the dark at 4˚C with mAbs against IL-4 (BD Bio-
sciences) and IFN-g (Caltag Laboratories) or appropriate isotype controls
(mouse IgG1-PE [BD Biosciences] and mouse IgG1-allophycocyanin
[Caltag Laboratories]) at recommended concentrations. Within 4 h stain-
ing, data from live cells, based on forward/side scatter profiles, were
acquired on a FACSCalibur flow cytometer (CellQuest software; BD
Biosciences) and analyzed with FlowJo (Tree Star, Ashland, OR).
Data analysis
Data analysis used Microsoft Excel and GraphPad Prism v4 (GraphPad
Software). Statistical analysis was performed by using paired parametric
and nonparametric tests as appropriate. A p value,0.05 was considered to
be statistically significant.
Results
IL-2–activated STAT5 binds to the C-MAF locus in vivo in
CD4 T cells
IL-2 is one of the earliest cytokines produced by activated T cells
and mediates its actions primarily through the activation of STAT5
proteins. A STAT5-ChIP assay was performed using chromatin
from freshly isolated CD4 T cells to identify in vivo IL-2–activated
STAT5 gene targets. The immunoprecipitated chromatin yielded a
number of distinct clones based on sequencing. One clone mapped
to chromosome 16 at 2152,916 to 2153,096 upstream of the
C-MAF gene and contained a consensus GAS motif (Fig. 1A). Be-
cause IL-2 and STAT5 play significant roles in gene regulation
during Th2 cell differentiation, we examined whether IL-2–in-
duced STAT5 also regulates C-MAF gene expression.
In vivo binding of STAT5 was assessed in cross-linked chromatin
fragments derived from either IL-2–stimulated or untreated freshly
isolated CD4 T cells by immunoprecipitation with anti-STAT5
Abs in a ChIP assay. DNA was isolated from precipitated chro-
matin and assayed for the presence of the upstream C-MAF se-
quence by using PCR with specific primers that detect the afore-
mentioned cloned fragment. IL-2 treatment induced binding of
STAT5a and STAT5b to this sequence (Fig. 1B). As expected,
this sequence was not enriched in the IL-2–treated sample by ChIP
performed with control IgG (Fig. 1B). Thus, there was specific IL-
2–induced binding of STAT5 proteins to a sequence upstream of
the C-MAF transcriptional start site (TSS). Because this sequence
is located at a long distance upstream of the TSS of the C-MAF
gene, we next determined whether IL-2–induced STAT5 binds to
other 59 upstream regions that were closer to the C-MAF promoter.
We postulated that transcriptionally relevant binding sites would
be located within cell type-specific DNase1 hypersensitive (DHS)
sites (29, 30).
The genome-wide DHS study of CD4 T cells identified three
DHS sites (DHS1–3) in the C-MAF 59-upstream region (Fig. 1C)
(30). DHS1 encompasses a broad region containing three peaks lo-
cated between 78,189,000 and 78,194,500 nucleotides (22,388 bp
FIGURE 1. STAT5 binding sites in the 59-upstream region of C-MAF were located within or adjacent to architectural regions of chromatin in resting and
Th2-differentiated CD4 T cells. A, Sequence of the cloned fragment obtained from STAT5-ChIP assay. Bold type indicates a consensus GAS motif; italic
type indicates a putative imperfect GAS motif, positioned at an optimal distance to facilitate tetrameric STAT5 binding. B, STAT5 binding to the cloned
sequence. ChIP was performed on untreated or IL-2–stimulated fresh CD4 T cells by using anti-STAT5a– or anti-STAT5b–specific Abs, or a negative con-
trol IgG Ab. Input is a sample of total chromatin taken before immunoprecipitation. C, Chromatin architecture of the C-MAF 59-upstream regulatory region
and positions of associated GAS motifs. Custom Track View (hg 16 build) is shown of DHS sites (DHS1–3), histone modifications H3K4me1, H3K4me3,
and H2A.Z in resting CD4 T cells, H3K4me3 in Th1 and Th2 cells, and positions of CpG islands in this region of chromosome 16 upstream of the TSS of
the C-MAF gene. The positions of consensus GAS motifs (GAS1–5) associated with the three DHSs are also indicated.
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upstream of TSS). DHS2 is between 78,232,000 and 78,233,000
nucleotides (239,888 bp upstream of TSS) and DHS3 is between
78,361,500 and 78,362,500 nucleotides (2169,388 bp upstream of
TSS). Analysis of the sequences within and around the three DHS
sites revealed the presence of five consensus GAS motifs. GAS1
and GAS5 were within the DHS1–3 peaks, whereas GAS2–4 were
nearby (Fig. 1C). Analysis of the sequence of these GAS motifs
revealed strong evolutionary conservation of GAS1 and GAS2,
suggesting that these may be important regulatory sequences,
whereas GAS3–5 were less well conserved (Supplemental Fig. 1).
To understand whether these GAS motifs coincided with tran-
scriptionally active chromatin during T cell differentiation, we
undertook ChIP-seq analysis of fully differentiated Th1 and Th2
cells using an anti-H3K4me3 Ab and compared sites of enrichment
with previously published genome-wide CD4 ChIP-seq data for
H3K4me1, H3K4me3, and H2AZ enrichment (10). These studies
revealed that GAS1, 2, 4, and 5 were located within regions en-
riched for monomethylated histone H3K4, whereas GAS1, 2, and 4
were also coincident with regions enriched for H3K4me3 in both
Th1 and Th2 cells (Fig. 1C). All of the GAS motifs coincided with
regions enriched for binding of the histone H2 variant H2A.Z. Thus,
despite being located a long distance upstream of the C-MAF TSS,
the distal GAS motifs mapped to regions containing chromatin
modifications consistent with potential enhancer function.
The TSS and the 59-upstream region of the c-maf gene are
depicted with the aforementioned sequences and positions of
DHS-associated GAS motifs (GAS1–5), as well as a negative
control GAS6, which is a random, consensus GAS motif (Fig. 2A).
To determine whether IL-2 induces in vivo binding of STAT5 to
each of the GAS motifs, we performed a ChIP analysis with anti-
STAT5a or control Ab on unstimulated or IL-2–stimulated, PHA-
activated human CD4 T cells. The immunoprecipitated chromatin
was analyzed for the specific enrichment of GAS1–6 motifs by
qRT-PCR. STAT5a bound to GAS1–4 in a specific IL-2–inducible
manner, but not to GAS5 or the negative control GAS6 (Fig. 2B).
The nonspecific IgG control did not enrich chromatin with GAS1–
6 sequences in IL-2–stimulated cells by ChIP (Fig. 2B). Thus, IL-
2 induced STAT5 binding to multiple sites in the C-MAF promoter
at varying distances 59 to the TSS, and these sites coincided with
markers of nucleosomal instability and potential enhancer func-
tion. We consistently noted that the lowest level of STAT5 binding
was to GAS3, suggesting that this GAS motif alone is insufficient
for optimum STAT5 binding. Comparison of the GAS3 sequence
(TTCTTTGAA) with the optimal STAT5 binding site [TTC(T/C)
N(G/A)GAA] reveals an imperfect match and may suggest a need
for cooperative tetrameric STAT5 binding to this region. In this
regard, we noted that there is an imperfect GAS motif spaced
seven nucleotides away from GAS3 (indicated in italic type in Fig.
1A), which may facilitate tetrameric STAT5 binding (28, 31).
To elucidate the STAT5-dependent enhancer activity of these
GAS motifs, we assessed the ability of transfected STAT5b to ac-
tivate constructs containing GAS motifs 1–4 in luciferase reporter
assays performed in an IL-2R reconstitution system in HEK293T
cells (28). These studies revealed that GAS1-, GAS2-, and GAS4-
driven luciferase reporter constructs increased IL-2–induced,
STAT5b-dependent transcriptional activation (Fig. 2C). A similar
pattern of transactivation of these reporter constructs was observed
with STAT5a (data not shown). The GAS3-driven luciferase re-
porter construct was not transactivated by STAT5b, consistent with
poor binding observed at this GAS motif (Fig. 2B). Thus, IL-2
induced specific STAT5 binding and transcriptional activation
from promoter proximal (GAS1, GAS2) and distal (GAS4) GAS
motifs within the C-MAF 59-upstream region.
IL-2 specifically induces C-MAF gene expression
The role of IL-2 in C-MAF gene expression was elucidated by
comparing C-MAF RNA levels from freshly isolated and PHA-
treated CD4 T cells that were untreated or treated with IL-2 for
0.5–12 h. C-MAF mRNA expression in these samples was ana-
lyzed by qPCR. IL-2 significantly induced C-MAF mRNA ex-
pression in both freshly isolated (Fig. 3A) and PHA-activated CD4
T cells (Fig. 3B) between 2 and 6 h after stimulation, and as early
as 30 min after stimulation. To determine whether IL-2 induction
of C-MAF gene transcription was associated with a concomitant
increase in protein expression, we prepared nuclear extracts from
preactivated CD4 T cells that were stimulated with IL-2 for the
indicated times and examined levels of C-MAF, phosphorylated
STAT5 (pY-STAT5), total STAT5, and the loading control lamin
B1 by immunoblot analysis. As shown in Fig. 3C, C-MAF protein
expression was clearly increased by 6 h after IL-2 treatment and
followed the peak increase in tyrosine phosphorylated STAT5
protein in the nucleus at 30 min. Of note, we observed the sus-
tained presence of IL-2–activated STAT5 in the nucleus for the
duration of the experiment (24 h) (Fig. 3C). Taken together,
FIGURE 2. IL-2–induced STAT5 binding and the regulatory effects of GAS motifs in the C-MAF 59-upstream region. A, Schematic outline of the chro-
mosomal locations (bp) of GAS1–5 and a negative control GAS motif (GAS6) relative to the C-MAF TSS on the left. B, Enrichment of chromatin from fresh
CD4 T cells by ChIP with anti-STAT5a as compared with control IgG. Sequences were analyzed by qRT-PCR for the different GASmotifs indicated in A. Data
are expressed as fold enrichment for IL-2–induced STAT5a binding for each site. Results are representative of three independent experiments from three
different donors. C, IL-2–induced STAT5-dependent transcriptional activation of GAS1-, GAS2-, and GAS4-driven luciferase constructs in HEK293T cells
reconstituted with IL-2Rb, gc, JAK3, and STAT5b by transfection. Pooled results from three independent experiments are shown. *p , 0.05.
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C-MAF is induced without TCR stimulation by IL-2 alone in
freshly isolated, as well as PHA-activated, CD4 T cells.
Because the cloned sequence from the STAT5-ChIP maps to a
59 region distal to the TSS of the C-MAF gene, we wanted to de-
termine whether IL-2–induced STAT5 may regulate either of the
flanking genes, namelyWWOX (∼380 kb 39 ofC-MAF) orDNCL2B
(∼940 kb 59 of C-MAF). We therefore performed qPCR analysis to
examine the IL-2–induced expression of these two genes in CD4
T cells. Neither WWOX nor DNCL2B was induced by IL-2 stimu-
lation (Fig. 3D). Thus, IL-2–induced binding of STAT5 to upstream
sequences specifically activates the C-MAF gene.
TCR plus CD28-mediated activation of C-MAF transcription
is dependent on IL-2R signaling
In the above studies, exogenous IL-2 alone efficiently stimulated
C-MAF expression in the absence of TCR stimulation. Thus, we
next examined whether TCR activation of C-MAF was dependent
on IL-2 signaling by using clinically relevant inhibitors of the
IL-2 receptor (HAT) or signaling molecule JAK3.
HAT (daclizumab) binds to the a-chain (CD25) of the high-
affinity IL-2R, inhibiting binding of IL-2 to the receptor com-
plex and causing efficient blockade of JAK3/STAT5 activation
(15). CD4 T cells were isolated from buffy coats and stimulated
with anti-CD3 plus anti-CD28 in the presence or absence of
HAT for the indicated times. As shown in Fig. 4A, C-MAF ex-
pression is significantly induced at 17 h after stimulation, and
HAT blocked this induction. Thus, the anti-CD3 plus anti-
CD28–stimulated early activation of C-MAF is dependent on
IL-2/IL-2R signaling.
Because IL-2 induction of C-MAF during T cell activation
may specifically involve activation of the JAK3/STAT5 pathway
or may use additional IL-2–dependent pathways, the effects of
a potent JAK3 inhibitor R333 (32) during TCR activation was
examined. Fresh CD4 T cells were purified and stimulated with
anti-CD3 plus anti-CD28 in the presence or absence of R333, and
total cell extracts and RNA were prepared for further analysis.
The effect of R333 on activation of STAT5 was investigated by
Western blot analysis of total cell extracts using phospho-STAT5
and pan-STAT5 Abs. STAT5 activation (pY-STAT5) was detect-
able as early as 4 h, increased by 17 h, and was blocked by R333
(Fig. 4B). Thus, the JAK3-specific inhibitor R333 efficiently
inhibited STAT5 activation.
RNA samples were analyzed by real-time PCR for C-MAF, IL2,
and CD25 expression. As noted in Fig. 4A, anti-CD3 plus anti-
CD28 activation of freshly isolated CD4 T cells increased C-MAF
transcription at 17 h after stimulation. JAK3 inhibitor R333
blocked the induction of C-MAF transcription (Fig. 4C). The in-
crease in CD25 and IL2 expression at 17 h posttreatment, fol-
lowing peak IL2 expression at 6–8 h (data not shown), was also
significantly reduced by R333 (Fig. 4C). Taken together, these
data indicated that the induction of C-MAF transcription during
T cell activation was dependent on IL-2 signaling and JAK3/
STAT5 activation in CD4 T cells.
IL-2 and IL-6 functionally synergize to potently induce C-MAF
gene expression
Because both IL-2 and IL-6 can independently activate C-MAF
expression and subsequently promote Th2 differentiation, we
FIGURE 3. C-MAF expression is specifically activated by IL-2. C-MAF transcription from freshly isolated (A) or PHA-activated CD4 T cells (B) that were
stimulated with IL-2 for the indicated times were assessed by qRT-PCR. Expression of PPIAwas used as the reference control. C-MAF mRNA levels are
presented as fold increase over unstimulated cells. Pooled results from three (A) and five (B) different donors are shown. *p , 0.05 relative to time 0. C,
C-MAF protein expression was potently induced in preactivated CD4 T cells by IL-2 treatment. IL-2 treatment activated STAT5 and induced nuclear
translocation of phopho-STAT5 at 30 min. Note that the 30-min sample is loaded to the left of the 0 time point sample on the gel. Nuclear extracts were
analyzed by Western blot analysis for c-MAF, STAT5, pY-STAT5, or a loading control, lamin B1, expression. D, IL-2 did not induce expression of the genes
WWOX or DNCL2B, which flank C-MAF. A schematic outline of the relative chromosomal locations (bp) of WWOX, C-MAF, and DNCL2B is shown. qRT-
PCR was performed on RNA from untreated or IL-2–treated freshly isolated CD4 T cells, using 18S rRNA expression as the reference gene. Pooled results
from four independent donors are shown. Expression ofWWOX and DNCL2B following IL-2 stimulation was not significantly different from that of control.
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examined whether these cytokines functionally cooperate in the
regulation of C-MAF. Purified CD4 T cells were stimulated as
above with anti-CD3 plus anti-CD28 or in the copresence of IL-2
and/or IL-6. As expected, C-MAF transcription was induced by
anti-CD3 plus anti-CD28 stimulation, and addition of either cy-
tokine alone modestly increased this induction. However, the
presence of both IL-2 and IL-6 significantly increased C-MAF
transcription in a synergistic manner (Fig. 5A). The presence of an
inhibitory Ab to IL-2 or CD25 or the JAK3 inhibitor R333 blocked
the synergy, indicating the increase was dependent on IL-2/IL-2R
signaling.
To understand whether this synergistic effect extended to in-
duction of GATA3, the signature transcription factor of Th2 cells,
we quantified GATA3 message in purified CD4 T cells stimulated
as above with anti-CD3 plus anti-CD28 or in the copresence of
IL-2 and/or IL-6. In contrast to C-MAF, we did not observe any
further increase in anti-CD3 plus anti-CD28–induced GATA3
mRNA expression by IL-2 or the combination of IL-2 plus IL-6
FIGURE 4. TCR-induced C-MAF expression is
dependent on IL-2 signaling via the JAK3/STAT5
pathway. A, CD4 T cells were stimulated by anti-
CD3 plus anti-CD28 treatment in the presence or
absence of HAT (10 mg/ml), and mRNA was pre-
pared at various time points after stimulation and
analyzed by qRT-PCR for C-MAF gene expression
using PPIA as reference control. C-MAF mRNA
levels are presented as fold increase over those
of unstimulated cells. Results are from three in-
dependent donors. *p , 0.05. B and C, CD4 T cells
were stimulated with anti-CD3 plus anti-CD28 in
the presence or absence of the JAK3 inhibitor R333
(5 mM) for the indicated times. B, STAT5 is acti-
vated in a JAK3-dependent manner following TCR
stimulation. Whole cell extracts were prepared from
cells after treatment. The activation of STAT5 (pY-
STAT5) was determined by Western blot analysis
using anti–phosphotyrosine-STAT5 and pan-STAT5
Abs and, as a loading control, anti-tubulin Ab. The
lack of pSTAT5 signal at 6 h was due to the loss of
sample during preparation, as indicated by the anti-
tubulin Western blot. C, Activation of C-MAF tran-
scription by TCR stimulation requires JAK3 activ-
ity. qRT-PCR analysis was performed to detect the
mRNA expression of C-MAF, CD25, and IL2 genes
using PPIA as the reference gene. mRNA expression
of each of the genes is presented as fold increase
over unstimulated cells. The results show pooled
data from four independent experiments. *p , 0.05.
FIGURE 5. IL-2 and IL-6 synergized to potently induce transcription of C-MAF, but not GATA3. CD4 T cells were stimulated with anti-CD3/anti-CD28
for 17 h in the presence of the indicated cytokines (IL-2, IL-6) and/or inhibitors. qRT-PCR was performed to assess mRNA expression of C-MAF and
GATA3 (A) and IL4 genes (B). Expression of each of the genes is presented as fold increase over unstimulated cells. In A and B, n = 5. *p , 0.05.
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(Fig. 5A). Thus, C-MAF transcription is specifically activated by
IL-2 signaling during early CD4 T cell activation.
IL-4 expression is dependent on IL-2 signaling during T cell
activation
The key Th2 cytokine gene IL4 is directly regulated by c-maf (19).
We wanted to clarify the role of IL-2 signaling in IL4 activation
during T cell activation. CD4 T cells were stimulated with anti-
CD3 plus anti-CD28 and IL-2 and IL-6 in the presence or absence
of the inhibitors anti–IL-2, HAT, or R333. As expected, IL4 ex-
pression is potently induced by the activating stimuli (Fig. 5B).
However, the addition of anti–IL-2, HAT, or R333 significantly
reduced IL4 gene expression, indicating that IL-2R signaling is
important for activation of IL4 transcription during T cell acti-
vation (Fig. 5B).
IL-2 signaling is required for IL-4 production during Th2 cell
differentiation
To determine whether IL-2 signaling was required for IL-4 protein
expression during in vitro Th2 cell polarization, we purified naive
CD4 T cells from cord blood samples from three donors and
performed in vitro differentiation experiments under Th2 polar-
izing conditions or TCR (anti-CD3 plus anti-CD28) plus IL-2
stimulation in the presence or absence of the IL-2R–blocking
HAT Ab. Fourteen days after treatment, cells were analyzed for
cytokine production by flow cytometry. A representative plot is
depicted in Fig. 6A, and the pooled results from all three donors
are presented in Fig. 6B. As expected, anti-CD3 plus anti-CD28
activation of naive T cells induced the production of both key Th1
(IFN-g) and Th2 cytokines (IL-4) (Fig. 6A) (26). HAT treatment
significantly reduced the percentage of IFN-g and IL-4 expressing
cells, consistent with previous studies using PBMCs (15). After
14 d under Th2 conditions, CD4 T cells produced predominantly
IL-4, not IFN-g (Fig. 6A). In the presence of HAT, IL-4 was
significantly inhibited by ∼90% in all three donors (Fig. 6). Fur-
thermore, when exogenous IL-2 was omitted in the skewing
experiments, the cells were unable to polarize to IL-4–producing
cells (Supplemental Fig. 2). Thus, these results indicated that IL-2
signaling plays an important role in the in vitro Th2 differentia-
tion of naive CD4 T cells.
Discussion
The pleiotropic actions of IL-2, one of the earliest cytokines
produced following T cell activation, are central to the propagation
of the ensuing immune response (33). During human T cell acti-
vation, functional blockade of the IL-2R with daclizumab blocks
STAT5 activation and inhibits Th1 and Th2 cytokine production
(15). We thus hypothesized that in humans IL-2/STAT5 may also
play a critical role in the differentiation of both these lineages. In
fully differentiated murine Th2 cells, target loci for Stat5 binding
have recently been identified by genome-wide ChIP-seq analysis.
These include motifs in the promoters of known key regulators of
Th2 differentiation in the mouse, such as il4r, gata3 and c-maf
(17). Because previous studies have revealed differences between
FIGURE 6. HAT inhibited IL-4 protein expression
during in vitro Th2 differentiation of naive CD4
T cells. A, Cord blood CD4 T cells were stimulated
with anti-CD3/anti-CD28 without or with HAT or un-
der Th2 skewing conditions without or with HAT for
14 d. Representative intracellular staining for IFN-g
and IL-4 in cord blood CD4 T cells that were activated
in vitro under Th2 skewing conditions (see Materials
and Methods) is shown from one of three independent
donors. B, Cumulative data from three experiments
showing mean percentage 6 SD of cells positive for
each cytokine. *p , 0.05.
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Th1/Th2 differentiation in humans and mice, we sought to es-
tablish the role of IL-2/STAT5 in human Th2 differentiation (26).
In this study, we show that IL-2 signaling plays a significant role
in initiating C-MAF and IL4 transcription during early T cell ac-
tivation and thus subsequent IL-4 production during differentia-
tion of human Th2-skewed human CD4 T cells.
The function of c-maf as an essential transcription factor re-
quired for IL-4–driven Th2 lineage commitment is well estab-
lished (19, 20). However, the molecular mechanisms that regulate
C-MAF expression prior to specific lineage differentiation are not
well understood. We show that during early T cell activation IL-2
increases C-MAF gene expression by inducing STAT5 binding to
GAS motifs located in the 59-upstream region. Of note, the STAT5
binding sites are not only located proximal to the promoter but
also at a large distance upstream of the TSS, and they map within
DHSs present in the genome of resting CD4 T cells (30). More-
over, these binding sites coincide with regions of enrichment of
the histone marks H2A.Z, H3K4me1, and H3K4me3, which in-
dicate structural features such as enhancers and therefore imply
regions of active chromatin. Thus, mechanistically, our studies
indicated that the C-MAF locus is already in a transcriptionally
permissive configuration in resting CD4 T cells. Furthermore, the
H3K4me3 enrichment pattern for this locus in resting CD4 T cells
(10) showed a similar pattern to that observed in Th1 and Th2
cells from our ChIP-seq analysis. Therefore, in different CD4
T cell lineages, similar regulatory regions appear to be involved
in “priming’ the C-MAF gene for cytokine-specific transcriptional
activation. c-maf is also important for murine Th17 differentia-
tion, where its expression is regulated by IL-6–activated Stat3
(21). Interestingly, a recent genome-wide ChIP-seq study of Stat3
binding sites in differentiated murine Th17 cells revealed that
Stat3 binds to a site that corresponds to the GAS1 region identified
in our study (34). Of note, the chromatin architecture in this region
appears to be very similar between WT and Stat32/2 mice, sug-
gesting that the c-maf chromatin architecture is unaffected by
Th17 lineage differentiation. This finding is consistent with our
present observation in human CD4 T cells that there are no major
changes in the C-MAF 59-upstream chromatin architecture be-
tween resting and Th1- and Th2-differentiated human CD4
T cells, and it supports the notion that the C-MAF locus is in an
epigenetically active configuration irrespective of differentiation
status and is primed for transcription before specific lineage dif-
ferentiation.
Additionally, we provide evidence that IL-2 alone can activate
C-MAF in freshly isolated T cells in the absence of TCR stim-
ulation, which we have also confirmed in CD4+CD252 T cells
(S. John, unpublished observations). Moreover, activation of
C-MAF occurs early during T cell activation, following increases
in IL-2 and CD25 transcription, and is blocked by functional
blockade of the IL-2R signaling (Fig. 4). Therefore, IL-2–in-
duced STAT5 is necessary for the expression of C-MAF during
early T cell activation. This finding is consistent with the ob-
servation that vav-deficient mice, which have impaired IL-2
production, also show lower expression of both c-maf and IL-4
and subsequent Th2 development (35, 36). Murine studies have
shown that c-maf is also induced by IL-6 via Stat3 activation,
leading to increased il4 expression and subsequent Th2 differ-
entiation (24, 37). However, in contrast to IL-2, IL-6 activation
of c-maf is dependent on TCR stimulation. Our data show that
IL-2 and IL-6 can synergize to more potently induce human
C-MAF gene expression, and that this synergy is significantly
inhibited by blocking IL-2 or IL-2R. Thus, both IL-2–activated
STAT5 and IL-6–activated STAT3 are important regulators of
C-MAF gene expression.
The IL-2/IL-2R blockade studies indicate that during T cell
activation, IL-2 signaling is not only required for C-MAF ex-
pression but also for early expression of IL4, indicating that early
in differentiation IL-2 plays an important role in creating an en-
vironment that favors Th2 polarization. We confirmed this func-
tionally by showing that blockade of high-affinity IL-2R with
daclizumab significantly inhibited in vitro Th2 polarization of
naive CD4 T cells, as evidenced by the significant decrease in IL-4
expression. Furthermore, there was no Th2 differentiation of
naive T cells when IL-2 was omitted in the in vitro polarization
experiments (Supplemental Fig. 2). Previously, murine studies
have shown that ICOS–ICOSL interactions are important for
c-maf and il2 expression and subsequent Th2 differentiation.
These studies showed that ICOS 1) can be induced in murine cells
by IL-4, 2) enhances IL-2 but not IL-4 production following
optimal stimulation through CD3 and CD28, and 3) is only im-
portant during suboptimal CD3/CD28 T cell stimulation or
through CD3 plus IL-2 alone (38–40). Because our experimental
set-up is APC-independent, we have not dissected the contribution
of ICOS–ICOSL interactions in this study in the anti-CD3 plus
anti-CD28/IL-2–mediated induction of human C-MAF and IL4. In
this regard, it will be interesting to elucidate whether IL4 and
C-MAF induction by IL-2 is only important during suboptimal
CD4 T cell activation, similar to murine T cells (40).
Although c-maf is important for Th2 differentiation, the critical
master regulator of this lineage is GATA3. As in previous murine
studies by others we did not find any evidence for the activation of
human GATA3 transcription by IL-2 or IL-6 at early times after
TCR activation. Similarly, previous murine studies showed that
neutralization of IL-2 had no effect on gata3 expression (41).
However, our data do not exclude the possibility that IL-2 may
regulate GATA3 RNA and/or protein levels in differentiated Th2
cells. Hwang et al. (42) have reported that c-maf enhances cd25
expression in developing murine Th2 cells, which is consistent
with our observation that blockade of IL-2R during anti-CD3 plus
anti-CD28 stimulation of CD4 T cells reduces CD25 expression.
Because our present studies reveal an important role for IL-2–
induced STAT5 in the activation of C-MAF, we speculate C-MAF
may play a role in the differentiation of peripheral human Tregs,
whose maintenance and functional integrity are dependent on this
pathway. We have observed that C-MAF transcription is induced
by anti-CD3 plus anti-CD28 and/or IL-2 stimulation in peripheral
human Tregs (B. Afzali and S. John, unpublished observations).
Although the functional implications of this observation are
presently unclear, it is suggestive of a role for C-MAF in Treg
biology and is supported by the finding that the aryl hydrocarbon
receptor can interact with c-maf to promote the differentiation of
type 1 regulatory cells in mice (43).
In summary, we have identified and characterized the molecu-
lar mechanism by which IL-2–induced STAT5 regulates the
Th2 lineage-promoting transcription factor C-MAF in a TCR-
independent manner. Furthermore, IL-2 synergizes with IL-6
during T cell activation to significantly promote activation of
C-MAF. Additionally, we show that the anti-CD3 plus anti-
CD28–induced activation of the critical Th2 cytokine IL-4 is
also dependent on IL-2 signaling. Finally, we demonstrate that
IL-4 expression during in vitro Th2 differentiation is inhibited
by functional IL-2R blockade. These findings help elucidate the
function of IL-2/IL-2R in human Th2 differentiation and support
the proposition that IL-2R–directed therapies, such as daclizu-
mab, may have utility in the treatment of allergic disorders.
Consistent with this suggestion, a recent controlled clinical trial
showed improvement of pulmonary function in asthmatic pa-
tients treated with daclizumab (44).
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